Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2010 1
2011 1
2012 4
2013 4
2014 4
2015 1
2016 3
2017 2
2018 2
2019 4
2020 4
2021 3
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Treatment outcomes with radium-223 in docetaxel-naïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan.
Chiang PC, Chiang PH, Chen IA, Chen YT, Wang HJ, Cheng YT, Kang CH, Chen CH, Liu YY, Su YL, Chen YH, Luo HL. Chiang PC, et al. Among authors: cheng yt. Medicine (Baltimore). 2023 Feb 3;102(5):e32671. doi: 10.1097/MD.0000000000032671. Medicine (Baltimore). 2023. PMID: 36749250 Free PMC article. Review.
The lowest level of tumor involvement is a significant prognostic factor for upper tract urothelial carcinoma after radical nephroureterectomy: A large retrospective cohort study.
Huang YC, Wang HJ, Sung MT, Chuang YC, Chen YT, Cheng YT, Kang CH, Liu HY, Chang YL, Chiang PH, Luo HL. Huang YC, et al. Among authors: cheng yt. Front Oncol. 2022 Dec 1;12:1031774. doi: 10.3389/fonc.2022.1031774. eCollection 2022. Front Oncol. 2022. PMID: 36530967 Free PMC article.
First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis.
Lin CT, Su PJ, Huang SY, Wu CC, Wang HJ, Cheng YT, Luo HL, Chen CH, Liu TT, Huang CC, Su YL. Lin CT, et al. Among authors: cheng yt. J Immunother. 2022 Nov-Dec 01;45(9):407-414. doi: 10.1097/CJI.0000000000000441. Epub 2022 Sep 20. J Immunother. 2022. PMID: 36121316 Free PMC article.
43 results